Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 5:00 PM
Ignite Modification Date: 2025-12-25 @ 2:41 PM
NCT ID: NCT01169350
Description: None
Frequency Threshold: 0
Time Frame: Adverse events were collected 24hr +/- 4 hours after each administration of [18F] FMISO.
Study: NCT01169350
Study Brief: 18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Diagnostic (18F FDG and 18F FMISO PET/CT) Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy. fludeoxyglucose F 18: Undergo 18F FDG and 18F FMISO PET/CT scans 18F-fluoromisonidazole: Undergo 18F FDG and 18F FMISO PET/CT scans positron emission tomography: Undergo 18F FDG and 18F FMISO PET/CT scans computed tomography: Undergo 18F FDG and 18F FMISO PET/CT scans laboratory biomarker analysis: Correlative studies 0 None 0 8 0 8 View
Serious Events(If Any):
Other Events(If Any):